BTN3A1 Specific Neutra™ Antibody Products

BTN3A1 (Butyrophilin Subfamily 3 Member A1), also known as BTF5 or CD277, is a crucial member of the immunoglobulin superfamily. BTN3A1 is a typical transmembrane glycoprotein that exists in various immune-related cells, including B cells, NK cells, T cells, dendritic cells, and endothelial cells. Evidence reveals that BTN3A1 is involved in T cell activation and immune response processes. In addition, BTN3A1 plays a critical role in regulating the release of cytokines from activated T cells.

Its Gene ID: 11119, UniProtKB ID: O00481, and OMIM ID: 613593.

Functions

BTN3A1 is a critical regulator in T cell activation and proliferation. In addition, BTN3A1 is involved in mediating T cell responses to infection. It is worth noting that the well-known function of BTN3A1 is to stimulate cells by binding phosphorylated antigens through specific domains. Furthermore, activation of BTN3A1 contributes to T cell proliferation and cytokine secretion. Based on the above reasons, BTN3A1 has gradually become a research hotspot in the field of immunity.

Fig.1 BTN3A1 promotes radioresistance by modulating autophagy.¹

BTN3A1 Pathways

It is reported that BTN3A1 can trigger T cell receptor (TCR) signaling by binding to the N-mannosylated residues of CD45. Furthermore, other pathways, such as PI3K/AKT and MAPK/ERK, may also be closely linked to the costimulatory properties of BTN3A1.

BTN3A1 and Carcinoma

A wealth of data reveals that BTN3A1 is expressed in various cancers, such as breast cancer, bladder cancer, ovarian cancer, pancreatic ductal adenocarcinoma, and renal cell carcinoma. Interestingly, the expression of BTN3A1 varies significantly in different cancers, for example, BTN3A1 expression is lower in breast cancer while BTN3A1 expression is high in advanced ovarian cancer. Furthermore, BTN3A1 is closely linked to prognosis in different cancers. Therefore, a deeper understanding of the role of BTN3A1 in different cancers may provide promising prospects for targeted therapy for cancer.

Therapies Targeting BTN3A1

There are data showing that specific antibodies targeting BTN3A1 can elicit T cell anti-tumor responses. Importantly, in ovarian cancer models, BTN3A1 targeting is shown to be superior to other therapies.

BTN3A1 Antibodies

At Creative Biolabs, our validated BTN3A1 antibodies are suited for scientific applications including flow cytometry, immunohistochemistry, and immunoprecipitation. Our diverse range of monoclonal, polyclonal, and neutralizing antibodies against BTN3A1 are primarily derived from mice and rabbits. To learn more about BTN3A1 antibodies, please contact us today.

REFERENCE

1. Yang, Wenjing, et al. "BTN3A1 promotes tumor progression and radiation resistance in esophageal squamous cell carcinoma by regulating ULK1-mediated autophagy." Cell Death & Disease 13.11 (2022): 984. Distributed under Open Access license CC BY 4.0, without modification.